
Research peptides
ARA-290
ARA-290 (cibinetide, also called pyroglutamate helix B surface peptide) is a synthetic 11-amino-acid peptide modeled on the helix B surface of erythropoietin. It was designed to separate erythropoietin's tissue-protective signaling from its effect on red blood cell production.
- Container
- Glass vial, crimp seal, flip-top cap
- Storage
- -20 °C, desiccated
- Paperwork
- Lot certificate (HPLC + mass spec) shown before you pay
Lot certificates
You’ll see American Peptides on the lab’s copy. They’re our supplier.
- 10 mg, lot ARA2901-0803: 99.72% purity (RP-HPLC), 10.86 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7616
Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.
What researchers study it for
- Small fiber neuropathy in sarcoidosis
- Neuropathy and metabolic control in type 2 diabetes
- Corneal nerve fiber measurements
- Diabetic macular edema
- Rodent models of nerve and tissue injury
How it is thought to work
ARA-290 is described as a selective agonist of the innate repair receptor, a heteromer of the erythropoietin receptor and the beta common receptor (CD131), reported to activate anti-inflammatory and tissue-repair pathways. In mice, its effect on allodynia after nerve injury was absent in animals lacking the beta common receptor. Most of the literature comes from one research network linked to the developer.
Where the research stands
Small phase 2 trials; not an approved medicine. Small phase 2 trials in sarcoidosis-associated neuropathy and type 2 diabetes reported changes in symptoms and corneal nerve fibers over 28 days. No approved product was found in Drugs@FDA.
Sources
- Brines M, et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences of the United States of America.
- Dahan A, et al. (2016). Targeting the innate repair receptor to treat neuropathy. Pain Reports.
- Culver DA, et al. (2017). Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Investigative Ophthalmology & Visual Science.
- Brines M, et al. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine.
For laboratory research use only. Not a drug, food, supplement or cosmetic; not for human or veterinary use. Nothing on this page is medical advice or a usage guide.
